Thanks Sleven. The answer sounded confident about the remainder of this year with the remaining commercial PBM plans, but did not want to commit to 2025. Sounded like they had already submitted offers for 2025. I may have missed it but don’t see any reference to the possibility of regaining CVS commercial. The last sentence makes me think that if they lose more coverage that that would spur them on to introduce the AG.

MrMain, at this point I follow your logic. The plan of getting Amarin to change the trajectory of the business first in order to then sell to BP and get a better valuation seemed to make sense. However, as you highlight, that may take so long, and with no guarantees of success, that taking less but getting a BP to take control now seems to make far more sense. No one can argue that BP (particularly a Euro centric one) wouldn’t have more success going forward. The big problem is whether there are any big fish that are interested in our little company.

Sleven I indicated that your link provided the information requested by the poster you responded to. I did not think I was blaming you for the PBM apologist writing the article. Apologies if you understood it to be.

Sleven, your link explains the mechanics of the functioning of PBMS, insurers, pharmacies, Pharma, etc., but unfortunately the title seems a little off. Most of everything out there seems to indicate that PBMs have raised costs.

As North has highlighted they are being sued by the FTC.

Whatever it will be, they announced it a month and a half prior to it. Of course there has to be some planning, but it seems it won’t be about something they didn’t know about on Oct 1 (probably before that).

Up over 7% on triple avg volume but I see no news.

I would hope that 3rd qtr would be the bottom but I am apprehensive about whether, come the New Year, some of the other PBMs follow CVS’s lead. But, as you allude to, Spain, UK, and others should start to pick up the pace and hopefully offset and add more than the losses in the US

Interesting that article was published one day after topline R-I results came out on Sept 24, 2018. Still not a huge uptake in V scripts until label expansion came in late Dec 2019. They accelerated until March 2020, when after the DuDisaster Amarin started to curtail sales and marketing expenses. It has been a slow ride down since for US scripts and anxiously awaiting next earnings report to see how made the CVS drop has made it.

Quite possible. But I’m not convinced that the scum bag PBMs would give a shit any more than they do now. Now, maybe with some legal wins in the infringement suit, that could have a bit of a chilling effect on the Generics, but that would involve time.

I think I have seen this in a number of cases. Company A sues company B, then B sues A, then they end up with some sort of settlement. All about leverage, but I agree the argument is ludicrous. If you have enough access to inventory to infringe (illegally I should add) on a larger indication how can you claim that you are being shut out of access to inventory?

Thanks North.

TCl1, thanks for the link. The last paragraph on a filing published Aug 8, 2024. My emphasis in bold

Sure, but are you saying that Amarin can or cannot market a generic version of V for the CVD indication?

Sleven, I assume that you are saying that since Amarin owns the patents that they would not be subject to those same requirements and can introduce an AG for the patented indication long before the patents expire. Appreciate the heads up.

MrMain, I agree and concur with your thinking on this. What I am unsure of is this whole business of releasing pertinent business information in a timely manner. Sort of their fiduciary duty to release information and not sit on it. Yet on the other hand, I can understand companies needing to keep certain business moves quiet for a time for competitive reasons. So like I said, I will at least be very interested to hear what they have to say. Not building my hopes up too high as our experience here has not been good but curious what this may be about. The new formulation, or an AG, or hopefully not, a RS.

Ram you raise an interesting question that I have not ever seen mentioned here (but I could have missed the discussion). I know that for typical generics an ANDA application has to be made to the FDA and if the patent has expired and other exclusivities are over and the drug meets some bioequivalence testing, then the FDA grants its permission. BUT does the same procedure apply to an authorized generic? I assume it would be but I really need to be educated on this. So like you say would it have to be an AG for VHTG and then just play the game that all the Generics play? Can't see how this could help them in their infringement cases as I would assume the defendants could bring this up. Funny if both litigants could be found guilty of breaking the law!

How does a side ( in this case Amarin) know whether the other side destroys some of that evidence and professes no knowledge of such? Do they get to forensically analyze their computers and phones or even get info from ISPs?

Yes, you are correct in that statement.

Dar, you are correct but the Affordable Care act limits health insurance companies not the drug manufacturers.

“limits the amount of premium income that health insurance companies can keep for profits, marketing, and administration through the Medical Loss Ratio (MLR) provision:

MLR threshold
The MLR threshold is 80% for individual and small group insurers, and 85% for large group insurers.

MLR rebates limits the amount of premium income that health insurance companies can keep for profits, marketing, and administration through the Medical Loss Ratio (MLR) provision”

I know I will probably be disappointed but I am looking forward to the Nov 14 Investor Day. Hoping to get more clarity on ww rollout and possibly some new piece of positive news.

Was just thinking a bit about not only this infringement case but also the CVS Caremark decision to drop brand V in their commercial coverage.

There had been some speculation here about some deal or whatever better term to describe it, between the Generics (or one of the Generics) to have CVS arrive at the decision to drop brand V from coverage. Unless seeing something to prove that, my first instinct is to not believe that there was some collusion in that sense. BUT if there was some agreement between the Generics and CVS Caremark to enable the exclusion of brand V, wouldn't that be compelling evidence of conspiring to infringe? I mean it would open the way for GV to be dispensed for every indication that a doc would write a script for and we know much of that is for the CVD indication.

That is very good news as we were thinking might happen, albeit still holding our breaths a bit. As you and others are more in tune with this legal stuff, do we have an idea as to the next developments in this case and when to expect them? Looking forward to discovery.

Was today’s late day drop option exp related? Seems it was steady almost the entire day and then wham.

Sounds reasonable. Is my understanding on this correct: that some say Italy has approved but we are just waiting on an announcement, and China is supposed to approve by the end of 2024?

Good question, which I think the BOD was thinking about when they postponed the share buyback.

First I would like to see the actual loss in revenues from the CVS decision and then see what the New Year brings in terms of possibly other insurers/PBMs dropping brand V coverage.

That must have been pretty well discounted as our stock here not doing much on the news.

Interesting that UNCY is up (albeit by not much), and ARDX slightly down today.

I would need to have knowledge and clarity about the new formulation and the company’s plans for it. Nonetheless, GIA would still be a poor path forward even with the introduction of the new formulation, unless it is the carrot to get BP to buy in.

Obviously something good. Look at the price and volume.

SD, I totally agree with you and have long said that the CVD should be enough to make everyone here very well off financially. What the number one or two killer isn’t enough? But like you say the GIA strategy was the dumbest move management could make. Not only AF, but no analyst was giving any kind of valuation for Europe. Posters on this board were denigrating all those analyst for not adequately valuing the EU side of the business. We of course now know that the analysts were right all along.

I supported Denner (still do since since he put his money on the line), but his experience makes me not so ashamed about my stock trading history. His first purchase of Amarin was for just under $5 a share. At the time I thought how could we go wrong holding here with such a seasoned investor piling in. Now the stock is at less than 1/8 of his original purchase.

Hard to believe that if GIA was such a poor strategy right after label expansion that it will be successful of getting us out of the deep hole we are in. As much as the prevailing idea of getting more reimbursements and increasing scripts before selling the company, that could be a very perilous path. It may just be better to consummate a deal at fire sale prices so that we at least get out with some skin on our backs - the shirt is long gone.

Thanks BF. This is the only study that I could find that involves IPE wrt to liver metastases. Study completion almost 2 years away ( 1 1/2 but we all know how these things go plus then waiting for results): https://clinicaltrials.gov/study/NCT03428477?cond=Liver%20Cancer&term=icosapent%20ethyl&rank=1&a=11

OT, another story highlighting the scum insurance companies:

https://www.statnews.com/2024/10/16/united-health-optum-care-medicare-advantage-strategy-dashboard-emails-documents/

Not very authoritative but saw comment posted on ST

5 active sites I see being reported but I unfortunately was not able to listen personally.

The link he posts for a “comprehensive analysis” does not seem to work for me. Can you or anyone else verify?

Since there is not much here today on this board, I thought I would do a little whining.

In my taxable account, AMRN is my only non-dividend paying stock (after retiring purchased divvy stocks for income), and in my retirement accounts AMRN is among several spec stocks although I have been gradually shifting those accounts into divvy stocks since next year I have to start taking RMDs. Looking at the portfolio, on the whole the stocks have done quite well, even those other spec stocks. BUT AMRN is amazing, in that even crappy stocks bounce every 6 or 12 months, but here with Amarin we are just mired in quicksand. If by some fluke this damn thing could pop up to $4 or $5, my financial situation would be set. Just hard to understand how this can just sit, sit, sit, slide, sit, sit, slide..... ad infinitum. I suppose, like I have said before, the market looks at future prospects and it does not comprehend how income can come in sufficiently fast enough to stem the losses. We need some new developments but damn if I can see any on the horizon. Anyway sorry for the rant.

227 times average volume today on no news that I can find. Obviously someone thinks they know something. Maybe they know nothing. We are always last to know.

Thanks for posting Sleven. Really good information. Wondering if with their last sentence they were slightly covering their asses by saying all this could be invalid if dietary cholesterol is consumed with say fat. Well an egg has 1.5g of sat fat. Quite possibly (don’t have time to check now) all sources of cholesterol have some quantity sat fat?